iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Purchased by Clearline Capital LP

Clearline Capital LP boosted its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 6.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 167,417 shares of the company’s stock after purchasing an additional 10,523 shares during the period. Clearline Capital LP’s holdings in iTeos Therapeutics were worth $1,709,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its holdings in shares of iTeos Therapeutics by 6.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock worth $164,000 after buying an additional 690 shares during the last quarter. Creative Planning increased its stake in iTeos Therapeutics by 6.5% during the third quarter. Creative Planning now owns 19,636 shares of the company’s stock worth $200,000 after acquiring an additional 1,196 shares during the last quarter. nVerses Capital LLC raised its position in iTeos Therapeutics by 212.5% in the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after purchasing an additional 1,700 shares during the period. Public Employees Retirement System of Ohio raised its position in iTeos Therapeutics by 4.9% in the first quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock valued at $532,000 after purchasing an additional 1,817 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on ITOS. Wells Fargo & Company assumed coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price objective for the company. JPMorgan Chase & Co. dropped their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research report on Friday, November 15th. Finally, Wedbush reissued an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research report on Tuesday, November 12th.

Insider Activity at iTeos Therapeutics

In other news, CFO Matthew Gall purchased 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the completion of the purchase, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 12.50% of the stock is currently owned by company insiders.

iTeos Therapeutics Price Performance

Shares of NASDAQ:ITOS opened at $8.55 on Monday. The firm has a market capitalization of $312.37 million, a PE ratio of -2.71 and a beta of 1.39. iTeos Therapeutics, Inc. has a 1 year low of $7.54 and a 1 year high of $18.75. The firm’s 50-day moving average is $9.13 and its two-hundred day moving average is $13.59.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. Analysts expect that iTeos Therapeutics, Inc. will post -3.46 EPS for the current fiscal year.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.